Comments
Alembic Pharmaceuticals on Friday said it has received approvals from the United States Food and Drug Administration for its Deferasirox tablets in the strengths of 90 mg and 360 mg and Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg, and 500 mg. The tablets are generic versions of Novartis Pharmaceuticals Corporation’s Jadenu tablets and Exjade tablets for oral suspension in the same strengths, it added. The company has also received tentative nod from the US health regulator for its Deferasirox tablets in the strength of 180 mg, Alembic Pharmaceuticals said. Shares of Alembic Pharma closed at ₹544.95, down 0.28 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.